Article ID Journal Published Year Pages File Type
8778532 European Urology 2018 9 Pages PDF
Abstract
Updated Alpharadin in Symptomatic Prostate Cancer (ALSYMPCA) trial findings show that radium-223 remained well tolerated during treatment and up to 3 yr after each patient's first injection.
Related Topics
Health Sciences Medicine and Dentistry Obstetrics, Gynecology and Women's Health
Authors
, , , , , , , , , , , , , ,